10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript

10x Genomics provides advanced tools for single cell and spatial biology research, serving academic and biopharma institutions worldwide.

Torex Gold Resources Inc. (TXG:CA) Q1 2026 Earnings Call Transcript

10x Genomics NASDAQ: TXG reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument platform that management described as the most significant product introduction in the company's history.

TXG beats Q1 estimates as consumables growth, margin expansion and lower operating costs narrow losses year over year.

10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript

10x Genomics (TXG) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.36 per share a year ago.

While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026.

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.